NovoCure Ltd
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
NVCR$11.81-5.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of
| December 31, | ||
|---|---|---|
| U.S. dollars in thousands | 2025 | 2024 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $93,548 | $163,767 |
| Short-term investments | 354,126 | 796,106 |
| Restricted cash | 9,842 | 2,327 |
| Trade receivables, net | 89,435 | 74,226 |
| Receivables and prepaid expenses | 58,669 | 35,063 |
| Inventories | 41,111 | 35,086 |
| Total current assets | 646,731 | 1,106,575 |
| Long-term assets: | ||
| Property and equipment, net | 77,606 | 77,660 |
| Field equipment, net | 22,066 | 14,811 |
| Right-of-use assets | 47,327 | 27,120 |
| Other long-term assets | 10,596 | 14,618 |
| Total long-term assets | 157,595 | 134,209 |
| Total assets | $804,326 | $1,240,784 |
| December 31, | ||
|---|---|---|
| U.S. dollars in thousands, except share and per share data | 2025 | 2024 |
| Liabilities and shareholders’ equity | ||
| Current liabilities: | ||
| Convertible note | $— | $558,160 |
| Trade payables | 122,231 | 105,086 |
| Other payables, lease liabilities and accrued expenses | 100,997 | 93,148 |
| Total current liabilities | 223,228 | 756,394 |
| Long-term liabilities: | ||
| Senior secured credit facility, net | 195,047 | 97,300 |
| Long term leases | 41,647 | 19,971 |
| Employee benefit liabilities | 3,938 | 6,940 |
| Total long-term liabilities | 240,632 | 124,211 |
| Total liabilities | 463,860 | 880,605 |
| Commitments and contingencies | ||
| Shareholders’ equity: | ||
| Share capital - | ||
| Ordinary shares - No par value, Unlimited shares authorized; Issued and outstanding: 112,492,667 shares and 108,516,819 shares at December 31, 2025 and December 31, 2024 respectively; | — | — |
| Additional paid-in capital | 1,634,264 | 1,519,809 |
| Accumulated other comprehensive income (loss) | (3,441) | (5,500) |
| Retained earnings (accumulated deficit) | (1,290,357) | (1,154,130) |
| Total shareholders’ equity | 340,466 | 360,179 |
| Total liabilities and shareholders’ equity | $804,326 | $1,240,784 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.